AI assistant
Ipsen — Report Publication Announcement 2015
Mar 31, 2015
1449_rf_2015-03-31_dc907737-ae53-460e-a21e-5268e6796eea.pdf
Report Publication Announcement
Open in viewerOpens in your device viewer
Regulated Information
The Ipsen Group publishes its 2014 Registration Document
Paris (France), 31 March 2015 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that its 2014 Registration Document has been filed with the French "Autorité des Marchés Financiers" (AMF) on 27 March 2015 and registered under the number D.15-0221.
The document is available on the company's website: www.ipsen.com and on the AMF's website: www.amf-france.org. Copies are also available at Ipsen's headquarters – 65 quai Georges Gorse, 92100 Boulogne-Billancourt – France.
The following documents are incorporated into the 2014 Registration Document:
- The Annual Financial Report;
- The Chairman's Report on the preparation and organization of the works of the Board of Directors and internal control procedures and risk management procedures and the corresponding Statutory Auditor's Report;
- The information relating to the fees paid to the Statutory Auditors.
About Ipsen
Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.2 billion in 2014. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in 30 countries. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. Ipsen's commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer or neuro-endocrine tumors. Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis, France; Slough/Oxford, UK; Cambridge, US). In 2014, R&D expenditure totaled close to €187 million, representing about 15% of Group sales. The Group has more than 4,500 employees worldwide. Ipsen's shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the "Service de Règlement Différé" ("SRD"). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.
For further information:
Media
Didier Véron Senior Vice-Président, Public Affairs and Communication Tel.: +33 (0)1 58 33 51 16 Fax: +33 (0)1 58 33 50 58 E-mail: [email protected]
Financial Community Stéphane Durant des Aulnois Vice-President Investor Relations Tel.: +33 (0)1 58 33 60 09 Fax: +33 (0)1 58 33 50 63 E-mail: [email protected]
Brigitte Le Guennec
Corporate External Communication Manager Tel.: +33 (0)1 58 33 51 17 Fax: +33 (0)1 58 33 50 58 E-mail : [email protected]